CNBC's "Fast Money" Markets Shrug Off Semi Weakness…And One Biopharma Stock Surges After Trial Results 6/24/24
Jun 24, 2024
The CEO of Alnylam discusses the positive results of a new heart drug, potentially impacting the biopharma space. Market trends analyze Nvidia's stock drop and its impact on related companies. Bank opportunities, yen interventions, and challenges faced by companies are also explored.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9
Intro
00:00 • 2min
Market Trends and Nvidia's Impact
02:11 • 11min
Bank Opportunities and Yen Interventions
13:17 • 7min
Financial Markets React to U.S. Prosecutors Urging Criminal Charges Against Boeing
20:14 • 2min
Challenges and Cultural Reinvention in Companies
22:08 • 3min
Stock Performance, Biotech Trial Results, and Market Update
25:36 • 2min
Analysis of a Biopharma Company's Dominance in Healthcare Sector and Stock Performance
27:44 • 2min
Analysis of the healthcare sector and a biopharma stock surge
29:15 • 2min
Biopharma Company's Stock Surges on Positive Drug Data
30:45 • 15min